I will need to ask my doctor regarding toxicity profile.Olga wrote:I do not know if there is any relevance of mitotic rate to an expected efficacy of the proposed regimen (probably not or no info) and I am not sure why it is discussed here, if it is interesting or thought to be relevant to Opdivo or ICI in general it could be discussed in the appropriate forum. Mitotic rate affects the efficacy of the traditional cytotoxic chemotherapy .
There is a searchable PDF of the abstracts presented at the CTOS 2016 https://www.ctos.org/Portals/0/PDF/CTOS ... m_Full.pdf I searched and can not find anything re. side effects or toxicities of the immune checkpoint inhibitors.
I also searched the web for the combination trials of Opdivo (nivolumab) plus vandetanib in any other diseases and could not find any but found that there were some trials of the nivolumab plus sunitinib or pazopanib (other TKI drugs) with some signs of the increased efficacy but you need to read more and the toxicity profile of the vandetanib could be different from sunitinib or pazopanib?
I've been on both sunitinib and pazopanib...and the reason why I think we are choosing to combine vandetanib with the opdivo is because vandetanib is the one i've been most recently taking. I had some limited success with vandetanib for 6 months, as did I with sutent and votrient. So I'm sure I could technically try opdivo with either sutent, votrient or vandetanib, but then I have to go through the process of obtaining access to these drugs. I probably have the option of taking opdivo without vandetanib, but I think my onco thinks that the combination may be more effective... Either way I'll ask rationale.